A Phase 4 interventional study of Infanrix hexa in Diphtheria, Hepatitis B and Acellular Pertussis, sponsored by GlaxoSmithKline. Completed at 29 sites in 6 countries. Open to participants aged 9 Months to 19 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-01-14.
Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Diphtheria — none open to participants now, none under way, none of them phase 3. diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine · Diphtheria.
Among the 15 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Diphtheria, this one is the 6th largest by enrollment, is one of 2 that started in 2016, is one of 6 in phase 4, and was the 14th registered.
268 studies on the registry are indexed under Diphtheria; 18 are open to participants now.
Browse Diphtheria studies →None of the 15 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Diphtheria is open now. The open studies under Diphtheria, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 11 Diphtheria studies recruiting now, 2 (18%) set no upper age limit and 9 (82%) stop at 75 or younger; 7 take children under 18; 10 take healthy volunteers.
This study: 9 Months to 19 Months · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 2 started in 2016.
This study's enrollment of 551 is above the median of 449 across 242 interventional studies indexed under Diphtheria.
Median enrollment 494 across the 15 interventional studies. Of the 15 that completed or were terminated, 11 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 15 have an industry lead sponsor. The 2 most frequent:
GlaxoSmithKline is the lead sponsor of 3,652 studies on the registry; 118 are open to participants now.
Of its 267 completed or terminated interventional studies of FDA-regulated products, 241 (90%) have results posted.
101 studies in Diphtheria by GlaxoSmithKline: none open now, 1 under way, 1 of them phase 3. Of 99 finished, 59 (60%) have results posted.
Among the 101 studies in Diphtheria by GlaxoSmithKline, this one is the 32nd largest by enrollment of the 92 interventional ones that give a count, is one of 5 that started in 2016, is one of 22 in phase 4, and was the 93rd registered.
GlaxoSmithKline’s Diphtheria studies by the year they started, since 1997.
None of the studies under way reaches primary completion within a year.
Among the 15 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Diphtheria, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 101 in Diphtheria:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the immunogenicity and safety of the Infanrix hexa booster dose given at 11-18 months of age to infants who received primary vaccination at 6-14 weeks. All infants in this booster study were born to pregnant women who participated in the study 116945 [DTPA (BOOSTRIX)-047] and having received the full primary vaccination series as per protocol requirement in study 201330 [DTPA (BOOSTRIX)-048.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
A vaccine not foreseen by the study protocol administered during the period starting from 30 days before the booster dose of study vaccine and ending 30 days after*, with the exception of inactivated influenza vaccine and other vaccines given as a part of the national/regional immunization schedule, that are allowed at any time during the study period.
Acute disease and/or fever at the time of vaccination.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This group will consist of healthy male or female infants, aged 9 months at the time of enrollment, born to mothers who received a single dose of Boostrix during pregnancy and a dose of placebo immediately post-delivery. All enrolled subjects in this group who will come back for subsequent visit will receive a booster dose of Infanrix hexa co-administered with Prevenar 13 according to the routine national/local immunization or study procedure
Biological: Infanrix hexa
This group will consist of healthy male or female infants, aged 9 months at the time of enrollment, born to mothers who received a dose of placebo during pregnancy and single dose of Boostrix immediately post-delivery. All enrolled subjects in this group who will come back for subsequent visit will receive a booster dose of Infanrix hexa co-administered with Prevenar 13 according to the routine national/local immunization or study procedure
Biological: Infanrix hexa
All subjects will receive Infanrix hexa co-administered with Prevenar13 as a booster dose.
Number of Seroprotected Subjects Against Anti-diphtheria (Anti-D), Anti-tetanus (Anti-T), Anti-hepatitis B (Anti-HBs), Anti-poliovirus Type 1, Anti-poliovirus Type 2, Anti-poliovirus Type 3 and Anti-polyribosyl-ribitol Phosphate (Anti-PRP)
Seroprotected subjects were defined as subjects with antibody concentrations/titres above or equal (≥) the assay cut-offs that are accepted immunological correlates of protection. 0.1 International units per milliliter (IU/ml) for anti-D and anti-T, 10 milli-International units per milliliter (mIU/mL) for anti-HB's, 8 Effective Dose 50 (ED50) for anti-polio virus (type 1,2,3) and 0.15 microgram/milliliter (µg/mL) for anti-PRP were considered as immunological correlates of protection.
Time frame: At one month after the booster dose (Day 30)
Number of Subjects With a Booster Response to Pertussis Antigens (Pertussis Toxoid (PT), Filamentous Haemagglutinin (FHA) and Pertactin (PRN))
Booster response to PT, FHA and PRN antigens was defined as: * for subjects with pre-vaccination antibody concentration below the assay cut-off, post-vaccination antibody concentration ≥ 4 times the assay cut-off, * for subjects with pre-vaccination antibody concentration between the assay cut-off and below 4 times the assay cut-off, post-vaccination antibody concentration ≥ 4 times the pre-vaccination antibody concentration, and * for subjects with pre-vaccination antibody concentration ≥ 4 times the assay cut-off, post-vaccination antibody concentration ≥ 2 times the pre-vaccination antibody concentration Seronegative (S-) subjects are those who have antibody concentration less than (\<) assay cut-off. Seropositive (S+) subjects are those who have antibody concentration ≥ assay cut-off prior to vaccination. Assay cut-off was 2.693 IU/mL for anti-PT, 2.046 IU/mL for anti- FHA and 2.187 IU/mL for anti-PRN
Time frame: At one month after the booster dose (Day 30)
Number of Seroprotected Subjects Against Anti-diphtheria, Anti-tetanus, Anti-poliovirus Type 1, Anti-poliovirus Type 2, Anti-poliovirus Type 3, Anti-HBs and Anti-PRP.
Seroprotected subjects were defined as subjects with antibody concentrations/titers above or equal (≥) the assay cut-offs that are accepted immunological correlates of protection. 0.1 IU/mL for anti-D and anti-T, 10 mIU/mL for anti-HB's, 8 ED50 for anti-polio virus (type 1,2,3) and 0.15 µg/mL for anti-PRP were considered as immunological correlates of protection.
Time frame: Before the booster dose (Day 0)
Number of Seropositive Subjects for Anti-PT, Anti-FHA and Anti-PRN
Seropositive subjects were defined as subjects whose antibody concentration/titre was greater than or equal to the assay cut-off. Assay cut-off was 2.693 IU/mL for anti-PT, 2.046 IU/mL for anti-FHA and 2.187 IU/mL for anti-PRN
Time frame: Before the booster dose (Day 0)
Number of Seropositive Subjects for Anti-pneumococcal Serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F)
Seropositive subjects were defined as subjects whose antibody concentration/titre was greater than or equal to the assay cut-off. Assay cut-off's for anti-pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) are 0.080 µg/mL, 0.075 µg/mL, 0.061 µg/mL, 0.198 µg/mL, 0.111 µg/mL, 0.102 µg/mL, 0.063 µg/mL, 0.66 µg/mL, 0.160 µg/mL, 0.111 µg/mL, 0.199 µg/mL, 0.163 µg/mL, 0.073 µg/mL respectively.
Time frame: Before the booster dose (Day 0)
Anti-D, Anti-T, Anti-PT, Anti-FHA, Anti-PRN Antibody Concentrations
Antibody concentrations are presented as Geometric Mean Concentrations (GMCs) and expressed in IU/mL.
Time frame: Before the booster dose (Day 0) and One month after the booster dose (Day 30)
Anti-poliovirus Type 1, 2, 3 Antibody Titres
Anti-Poliovirus type 1, 2 and 3 antibody titers were expressed as Geometric Mean Titers (GMT).
Time frame: Before the booster dose (Day 0) and One month after the booster dose (Day 30)
Anti-HBs Antibody Concentrations
Antibody concentrations are presented as Geometric Mean Concentrations (GMCs) and expressed in mIU/mL.
Time frame: Before the booster dose (Day 0) and One month after the booster dose (Day 30)
Anti-pneumococcal Serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) and Anti-PRP Antibody Concentrations
Antibody concentrations are presented as Geometric Mean Concentrations (GMCs) and expressed in µg/mL.
Time frame: Before the booster dose (Day 0) and One month after the booster dose (Day 30)
Number of Seropositive Subjects for Anti-PT, Anti-FHA and Anti-PRN.
Seropositive subjects were defined as subjects whose antibody concentration/titre was greater than or equal to the assay cut-off. Assay cut-off was 2.693 IU/mL for anti-PT, 2.046 IU/mL for anti- FHA and 2.187 IU/mL for anti-PRN
Time frame: At one month after the booster dose (Day 30)
Number of Subjects With Solicited Local Symptoms
Assessed solicited local symptoms were pain, redness, swelling. Any redness, swelling is defined as a symptom with a surface diameter greater than 0 millimeter
Time frame: During the 4-day (Day 0-Day 3) follow-up period after booster vaccination of two vaccines (Infanrix hexa and Prevenar 13)
Number of Subjects With Solicited General Symptoms
Assessed solicited general symptoms were Drowsiness, Fever, Irritability/Fussiness and Loss of appetite. Fever was defined as temperature ≥37.5 degree Celsius (°C) /99.5 degree Fahrenheit (°F) for oral, axillary or tympanic route, or ≥38.0°C/100.4°F on rectal route.
Time frame: During the 4-day (Day 0-Day 3) follow-up period after booster vaccination
Number of Subjects With Unsolicited Adverse Events (AEs)
An AE was any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Time frame: During the 31-day (Day 0-Day 30) follow-up period after booster vaccination
Number of Subjects With Serious Adverse Events (SAEs)
SAE is any untoward medical occurrence that results in death, is life threatening, requires hospitalisation or prolongation of existing hospitalisation, resulting in disability/incapacity
Time frame: From booster dose up to study end (approximately 6 or 7 months, per subject)
Number of Subjects With an ASQ-3 Score (Ages & Stages Questionnaires, Third Edition) in the Black Zone
Neurodevelopmental status was measured by ASQ-3 score scale \[ASQ-3, 2016\] in the black zone. The ASQ-3 included a series of questions designed to assess 5 areas of development (communication, gross motor, fine motor, problem solving, and personal-social). Any subject who scored below the cut-off i.e., a score more than 2 Standard Deviations (SDs) below the mean score for the U.S. reference group (i.e., black zone in the score chart) in any of the 5 domains of the ASQ-3 was to be referred to a developmental specialist for a formal neurodevelopmental assessment (using the Bayley Scale for Infant Development, Version III \[BSID-III\])
Time frame: At 9 months of age, 18 months of age, and 9 or 18 months of age
Number of Subjects Referred for Formal Neurodevelopmental Evaluation Using BSID-III (Bayley Scale for Infant Development, Version III)
Any subject who scored below the cut-off i.e., a score more than 2 Standard Deviations (SDs) below the mean score for the U.S. reference group (i.e., black zone in the score chart) in any of the 5 domains of the ASQ-3 was referred to a developmental specialist for a formal neurodevelopmental assessment (using the Bayley Scale for Infant Development, Version III BSID-III)
Time frame: At 9 months of age, 18 months of age, and 9 or 18 months of age
Estimated Proportion of Infants With at Least One of the Indicators of Neurodevelopmental Impairment Using BSID-III (Bayley Scale for Infant Development, Version III)
The estimated proportion (expressed in percentage) of infants with a BSID-III indicator of neurodevelopmental delay was based on ASQ-3 black zone indicator and subsequent BSID-III assessment using the following formula: 100 \* (Number of subjects with ASQ-3 below cut off / Number of enrolled subjects with available results) \* (Number of subjects with at least one indicator of neurodevelopmental delay using BSID III / Number of subjects referred for BSID III evaluation)
Time frame: At 9 months of age, 18 months of age, and 9 or 18 months of age
Subjects enrolled in the study were infants aged 9 months at the time of enrollment, born to mothers vaccinated with Boostrix in study 116945 BOOSTRIX-047 \[NCT02377349\] and who received primary vaccination Infanrix hexa co-administered with Prevenar 13 in study 201330 BOOSTRIX-048 \[NCT0242264\]
| Milestone | dTpa Group | Control Group |
|---|---|---|
| Started | 270 | 281 |
| Vaccinated | 263 | 277 |
| Completed | 259 | 277 |
| Not completed | 11 | 4 |
| Withdrew: Lost to follow-up | 3 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Subjects enrolled but not vaccinated | 7 | 4 |
Seroprotected subjects were defined as subjects with antibody concentrations/titres above or equal (≥) the assay cut-offs that are accepted immunological correlates of protection. 0.1 International units per milliliter (IU/ml) for anti-D and anti-T, 10 milli-International units per milliliter (mIU/mL) for anti-HB's, 8 Effective Dose 50 (ED50) for anti-polio virus (type 1,2,3) and 0.15 microgram/milliliter (µg/mL) for anti-PRP were considered as immunological correlates of protection.
| Participants | dTpa Group | Control Group |
|---|---|---|
| Anti-D | 221 | 247 |
| Anti-T | 221 | 247 |
| Anti-HBs | 215 | 239 |
| Anti-polio 1 | 204 | 228 |
| Anti-polio 2 | 201 | 227 |
| Anti-polio 3 | 188 | 210 |
| Anti-PRP | 221 | 246 |
Booster response to PT, FHA and PRN antigens was defined as: * for subjects with pre-vaccination antibody concentration below the assay cut-off, post-vaccination antibody concentration ≥ 4 times the assay cut-off, * for subjects with pre-vaccination antibody concentration between the assay cut-off and below 4 times the assay cut-off, post-vaccination antibody concentration ≥ 4 times the pre-vaccination antibody concentration, and * for subjects with pre-vaccination antibody concentration ≥ 4 times the assay cut-off, post-vaccination antibody concentration ≥ 2 times the pre-vaccination antibody concentration Seronegative (S-) subjects are those who have antibody concentration less than (\<) assay cut-off. Seropositive (S+) subjects are those who have antibody concentration ≥ assay cut-off prior to vaccination. Assay cut-off was 2.693 IU/mL for anti-PT, 2.046 IU/mL for anti- FHA and 2.187 IU/mL for anti-PRN
| Participants | dTpa Group | Control Group |
|---|---|---|
| Anti-PT, S- | 62 | 40 |
| Anti-PT, S+ (< 4*assay cut-off) | 98 | 124 |
| Anti-PT, S+ (≥ 4*assay cut-off) | 38 | 71 |
| Anti-PT, Overall | 198 | 235 |
| Anti-FHA, S- | 8 | 3 |
| Anti-FHA, S+ (< 4*assay cut-off) | 83 | 58 |
| Anti-FHA, S+ (≥ 4*assay cut-off) | 117 | 172 |
| Anti-FHA, Overall | 208 | 233 |
| Anti-PRN, S- | 34 | 31 |
| Anti-PRN, S+ (< 4*assay cut-off) | 90 | 76 |
| Anti-PRN, S+ (≥ 4*assay cut-off) | 86 | 133 |
| Anti-PRN, Overall | 210 | 240 |
Seroprotected subjects were defined as subjects with antibody concentrations/titers above or equal (≥) the assay cut-offs that are accepted immunological correlates of protection. 0.1 IU/mL for anti-D and anti-T, 10 mIU/mL for anti-HB's, 8 ED50 for anti-polio virus (type 1,2,3) and 0.15 µg/mL for anti-PRP were considered as immunological correlates of protection.
| Participants | dTpa Group | Control Group |
|---|---|---|
| Anti-D | 181 | 220 |
| Anti-T | 215 | 232 |
| Anti-HBs | 206 | 229 |
| Anti-polio 1 | 188 | 212 |
| Anti-polio 2 | 188 | 215 |
| Anti-polio 3 | 188 | 215 |
| Anti-PRP | 161 | 166 |
Seropositive subjects were defined as subjects whose antibody concentration/titre was greater than or equal to the assay cut-off. Assay cut-off was 2.693 IU/mL for anti-PT, 2.046 IU/mL for anti-FHA and 2.187 IU/mL for anti-PRN
| Participants | dTpa Group | Control Group |
|---|---|---|
| Anti-PT | 153 | 201 |
| Anti-FHA | 215 | 241 |
| Anti-PRN | 187 | 213 |
Seropositive subjects were defined as subjects whose antibody concentration/titre was greater than or equal to the assay cut-off. Assay cut-off's for anti-pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) are 0.080 µg/mL, 0.075 µg/mL, 0.061 µg/mL, 0.198 µg/mL, 0.111 µg/mL, 0.102 µg/mL, 0.063 µg/mL, 0.66 µg/mL, 0.160 µg/mL, 0.111 µg/mL, 0.199 µg/mL, 0.163 µg/mL, 0.073 µg/mL respectively.
| Participants | dTpa Group | Control Group |
|---|---|---|
| Anti-pneumococcal serotype 1 | 196 | 214 |
| Anti-pneumococcal serotype 3 | 122 | 147 |
| Anti-pneumococcal serotype 4 | 189 | 215 |
| Anti-pneumococcal serotype 5 | 163 | 182 |
| Anti-pneumococcal serotype 6A | 196 | 219 |
| Anti-pneumococcal serotype 6B | 175 | 205 |
| Anti-pneumococcal serotype 7F | 210 | 232 |
| Anti-pneumococcal serotype 9V | 203 | 225 |
| Anti-pneumococcal serotype 14 | 201 | 223 |
| Anti-pneumococcal serotype 18C | 168 | 190 |
| Anti-pneumococcal serotype 19A | 148 | 172 |
| Anti-pneumococcal serotype 19F | 183 | 202 |
| Anti-pneumococcal serotype 23F | 160 | 191 |
Antibody concentrations are presented as Geometric Mean Concentrations (GMCs) and expressed in IU/mL.
| IU/ml | dTpa Group | Control Group |
|---|---|---|
| Anti-D at Day 0 | 0.207 (0.184 to 0.234) | 0.322 (0.285 to 0.363) |
| Anti-D at Day 30 | 6.114 (5.577 to 6.703) | 8.402 (7.694 to 9.174) |
| Anti-T at Day 0 | 0.753 (0.646 to 0.878) | 0.578 (0.506 to 0.659) |
| Anti-T at Day 30 | 8.200 (7.324 to 9.180) | 6.758 (6.143 to 7.433) |
| Anti-PT at Day 0 | 4.4 (3.8 to 5.0) | 6.3 (5.5 to 7.1) |
| Anti-PT at Day 30 | 52.4 (46.9 to 58.4) | 80.3 (73.3 to 88.1) |
| Anti-FHA at Day 0 | 11.2 (9.6 to 13.1) | 16.5 (14.4 to 18.8) |
| Anti-FHA at Day 30 | 152.5 (136.3 to 170.6) | 187.2 (172.7 to 202.9) |
| Anti-PRN at Day 0 | 6.9 (5.8 to 8.2) | 9.6 (8.3 to 11.2) |
| Anti-PRN at Day 30 | 333.9 (285.4 to 390.7) | 262.3 (230.9 to 298.1) |
Anti-Poliovirus type 1, 2 and 3 antibody titers were expressed as Geometric Mean Titers (GMT).
| Titers | dTpa Group | Control Group |
|---|---|---|
| Anti-polio 1 at Day 0 | 64.9 (52.0 to 80.9) | 83.3 (67.7 to 102.5) |
| Anti-polio 1 at Day 30 | 1611.7 (1381.2 to 1880.6) | 1532.1 (1322.2 to 1775.3) |
| Anti-polio 2 at Day 0 | 71.7 (57.6 to 89.4) | 79.2 (64.4 to 97.5) |
| Anti-polio 2 at Day 30 | 2232.4 (1931.2 to 2580.5) | 2371.2 (2097.9 to 2680.1) |
| Anti-polio 3 at Day 0 | 106.0 (84.1 to 133.4) | 118.4 (97.0 to 144.5) |
| Anti-polio 3 at Day 30 | 2944.6 (2529.4 to 3427.9) | 2891.8 (2496.2 to 3350.2) |
Antibody concentrations are presented as Geometric Mean Concentrations (GMCs) and expressed in mIU/mL.
| mIU/mL | dTpa Group | Control Group |
|---|---|---|
| Anti-HBs at Day 0 | 158.7 (129.9 to 194.0) | 193.4 (158.4 to 236.1) |
| Anti-HBs at Day 30 | 4858.3 (3918.4 to 6023.7) | 5031.2 (4072.7 to 6215.4) |
Antibody concentrations are presented as Geometric Mean Concentrations (GMCs) and expressed in µg/mL.
| µg/mL | dTpa Group | Control Group |
|---|---|---|
| Anti-PnPS 1 at Day 0 | 0.22 (0.19 to 0.24) | 0.27 (0.24 to 0.30) |
| Anti-PnPS 1 at Day 30 | 3.22 (2.88 to 3.60) | 3.64 (3.28 to 4.04) |
| Anti-PnPS 3 at Day 0 | 0.08 (0.07 to 0.09) | 0.10 (0.09 to 0.11) |
| Anti-PnPS 3 at Day 30 | 0.59 (0.53 to 0.65) | 0.62 (0.57 to 0.69) |
| Anti-PnPS 4 at Day 0 | 0.15 (0.13 to 0.16) | 0.19 (0.17 to 0.22) |
| Anti-PnPS 4 at Day 30 | 2.91 (2.54 to 3.33) | 3.28 (2.89 to 3.72) |
| Anti-PnPS 5 at Day 0 | 0.33 (0.29 to 0.37) | 0.34 (0.31 to 0.38) |
| Anti-PnPS 5 at Day 30 | 2.66 (2.39 to 2.97) | 2.81 (2.52 to 3.14) |
| Anti-PnPS 6A at Day 0 | 0.38 (0.33 to 0.43) | 0.44 (0.39 to 0.50) |
| Anti-PnPS 6A at Day 30 | 9.07 (8.05 to 10.22) | 9.49 (8.45 to 10.67) |
| Anti-PnPS 6B at Day 0 | 0.29 (0.25 to 0.33) | 0.33 (0.29 to 0.38) |
| Anti-PnPS 6B at Day 30 | 7.83 (6.82 to 8.98) | 8.00 (7.06 to 9.06) |
| Anti-PnPS 7F at Day 0 | 0.49 (0.44 to 0.54) | 0.56 (0.51 to 0.61) |
| Anti-PnPS 7F at Day 30 | 5.00 (4.55 to 5.50) | 4.96 (4.50 to 5.48) |
| Anti-PnPS 9V at Day 0 | 0.26 (0.23 to 0.29) | 0.32 (0.28 to 0.36) |
| Anti-PnPS 9V at Day 30 | 3.74 (3.35 to 4.16) | 3.91 (3.52 to 4.35) |
| Anti-PnPS 14 at Day 0 | 0.97 (0.85 to 1.11) | 1.19 (1.04 to 1.37) |
| Anti-PnPS 14 at Day 30 | 10.36 (9.22 to 11.64) | 11.62 (10.34 to 13.06) |
| Anti-PnPS 18C at Day 0 | 0.19 (0.17 to 0.21) | 0.23 (0.21 to 0.26) |
| Anti-PnPS 18C at Day 30 | 3.23 (2.86 to 3.65) | 3.57 (3.21 to 3.98) |
| Anti-PnPS 19A at Day 0 | 0.32 (0.27 to 0.37) | 0.37 (0.32 to 0.43) |
| Anti-PnPS 19A at Day 30 | 7.90 (7.06 to 8.83) | 8.68 (7.82 to 9.63) |
| Anti-PnPS 19F at Day 0 | 0.37 (0.32 to 0.43) | 0.47 (0.41 to 0.55) |
| Anti-PnPS 19F at Day 30 | 7.66 (6.84 to 8.57) | 8.63 (7.75 to 9.62) |
| Anti-PnPS 23F at Day 0 | 0.14 (0.12 to 0.16) | 0.19 (0.16 to 0.22) |
| Anti-PnPS 23F at Day 30 | 2.07 (1.83 to 2.34) | 2.38 (2.10 to 2.69) |
| Anti-PRP at Day 0 | 0.371 (0.303 to 0.453) | 0.292 (0.244 to 0.349) |
| Anti-PRP at Day 30 | 26.186 (22.610 to 30.327) | 19.714 (16.891 to 23.010) |
Seropositive subjects were defined as subjects whose antibody concentration/titre was greater than or equal to the assay cut-off. Assay cut-off was 2.693 IU/mL for anti-PT, 2.046 IU/mL for anti- FHA and 2.187 IU/mL for anti-PRN
| Participants | dTpa Group | Control Group |
|---|---|---|
| Anti-PT | 220 | 247 |
| Anti-FHA | 221 | 247 |
| Anti-PRN | 220 | 247 |
Assessed solicited local symptoms were pain, redness, swelling. Any redness, swelling is defined as a symptom with a surface diameter greater than 0 millimeter
| Participants | dTpa Group | Control Group |
|---|---|---|
| Pain | 134 | 154 |
| Redness | 143 | 169 |
| Swelling | 119 | 122 |
Assessed solicited general symptoms were Drowsiness, Fever, Irritability/Fussiness and Loss of appetite. Fever was defined as temperature ≥37.5 degree Celsius (°C) /99.5 degree Fahrenheit (°F) for oral, axillary or tympanic route, or ≥38.0°C/100.4°F on rectal route.
| Participants | dTpa Group | Control Group |
|---|---|---|
| Drowsiness | 128 | 138 |
| Irritability | 163 | 188 |
| Loss of Appetite | 104 | 116 |
| Fever | 73 | 85 |
An AE was any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
| Participants | dTpa Group | Control Group |
|---|---|---|
| Number of Subjects With Unsolicited Adverse Events (AEs) | 94 | 111 |
SAE is any untoward medical occurrence that results in death, is life threatening, requires hospitalisation or prolongation of existing hospitalisation, resulting in disability/incapacity
| Participants | dTpa Group | Control Group |
|---|---|---|
| Number of Subjects With Serious Adverse Events (SAEs) | 0 | 3 |
Neurodevelopmental status was measured by ASQ-3 score scale \[ASQ-3, 2016\] in the black zone. The ASQ-3 included a series of questions designed to assess 5 areas of development (communication, gross motor, fine motor, problem solving, and personal-social). Any subject who scored below the cut-off i.e., a score more than 2 Standard Deviations (SDs) below the mean score for the U.S. reference group (i.e., black zone in the score chart) in any of the 5 domains of the ASQ-3 was to be referred to a developmental specialist for a formal neurodevelopmental assessment (using the Bayley Scale for Infant Development, Version III \[BSID-III\])
| Participants | dTpa Group | Control Group |
|---|---|---|
| Any domain at Month 9 | 27 | 28 |
| Communication at Month 9 | 1 | 3 |
| Gross motor skills at Month 9 | 14 | 19 |
| Fine motor at Month 9 | 8 | 3 |
| Problem solving at Month 9 | 7 | 6 |
| Personal- Social at Month 9 | 2 | 2 |
| Any domain at Month 18 | 6 | 5 |
| Communication at Month 18 | 1 | 0 |
| Gross motor skills at Month 18 | 3 | 2 |
| Fine motor at Month 18 | 1 | 1 |
| Problem solving at Month 18 | 1 | 3 |
| Personal- Social at Month 18 | 0 | 0 |
| Any domain at Month 9 or 18 | 31 | 31 |
| Communication at Month 9 or 18 | 2 | 3 |
| Gross motor skills at Month 9 or 18 | 16 | 20 |
| Fine motor at Month 9 or 18 | 9 | 4 |
| Problem solving at Month 9 or 18 | 8 | 8 |
| Personal- Social at Month 9 or 18 | 2 | 2 |
Any subject who scored below the cut-off i.e., a score more than 2 Standard Deviations (SDs) below the mean score for the U.S. reference group (i.e., black zone in the score chart) in any of the 5 domains of the ASQ-3 was referred to a developmental specialist for a formal neurodevelopmental assessment (using the Bayley Scale for Infant Development, Version III BSID-III)
| Participants | dTpa Group | Control Group |
|---|---|---|
| Any Domain at Month 9 | 16 | 14 |
| Any Domain at Month 18 | 6 | 3 |
| Any Domain at Month 9 or 18 | 20 | 17 |
The estimated proportion (expressed in percentage) of infants with a BSID-III indicator of neurodevelopmental delay was based on ASQ-3 black zone indicator and subsequent BSID-III assessment using the following formula: 100 \* (Number of subjects with ASQ-3 below cut off / Number of enrolled subjects with available results) \* (Number of subjects with at least one indicator of neurodevelopmental delay using BSID III / Number of subjects referred for BSID III evaluation)
| Percentage of Infants | dTpa Group | Control Group |
|---|---|---|
| Any domain at Month 9 | 4.39 (2.1 to 8.0) | 5.69 (3.0 to 9.6) |
| Any domain at Month 18 | 1.17 (0.2 to 3.4) | 0.61 (0.1 to 2.8) |
| Any domain at Month 9 or 18 | 4.61 (2.3 to 8.2) | 5.84 (3.2 to 9.7) |
Collected over Solicited symptoms were collected during the 4-day (Day 0 - Day 3) follow-up period after each vaccination. Unsolicited AEs were collected during the 31-day (Day 0 - Day 30) follow-up period after each vaccination. SAEs were collected from booster dose up to study end (approximately 6 or 7 months, per subject). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| dTpa Group | 0/263 (0%) | 0/263 (0%) | 232/263 (88.2%) |
| Control Group | 0/277 (0%) | 3/277 (1.1%) | 257/277 (92.8%) |
| Event | dTpa Group | Control Group |
|---|---|---|
| Periorbital cellulitisInfections and infestations | 0/263 | 1/277 |
| PneumoniaInfections and infestations | 0/263 | 1/277 |
| Sleep apnoea syndromeRespiratory, thoracic and mediastinal disorders | 0/263 | 1/277 |
| Event | dTpa Group | Control Group |
|---|---|---|
| IrritabilityPsychiatric disorders | 163/263 | 189/277 |
| Injection site erythemaGeneral disorders | 143/263 | 169/277 |
| Injection site painGeneral disorders | 134/263 | 154/277 |
| SomnolenceNervous system disorders | 128/263 | 138/277 |
| Injection site swellingGeneral disorders | 119/263 | 122/277 |
| Decreased appetiteMetabolism and nutrition disorders | 104/263 | 116/277 |
| PyrexiaGeneral disorders | 81/263 | 101/277 |
| NasopharyngitisInfections and infestations | 12/263 | 10/277 |
| Ear infectionInfections and infestations | 9/263 | 12/277 |
| VomitingGastrointestinal disorders | 10/263 | 8/277 |
| Age, Customized(Participants) | dTpa Group | Control Group | Total |
|---|---|---|---|
| Infants and toddlers (28 days-23 months) | 270 | 281 | 551 |
| Sex: Female, Male(Participants) | dTpa Group | Control Group | Total |
|---|---|---|---|
| Female | 127 | 128 | 255 |
| Male | 143 | 153 | 296 |
| Race/Ethnicity, Customized(Participants) | dTpa Group | Control Group | Total |
|---|---|---|---|
| African Heritage / African American | 4 | 9 | 13 |
| Asian - East Asian Heritage | 1 | 0 | 1 |
| Asian - South East Asian Heritage | 2 | 0 | 2 |
| White - Arabic / North African Heritage | 1 | 3 | 4 |
| White - Caucasian / European Heritage | 246 | 262 | 508 |
| Other | 16 | 7 | 23 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Sep 2016 to primary completion in Mar 2019, 30 months.
Results were first posted in Jan 2020, 9 months after primary completion.
Of 21 phase 4 interventional studies under Diphtheria, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 30. This study's 30 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine